If you have been reading about Synthetic peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Approximate, for sequence GEPPPGKPADDAGLV |
| Molecular mass | ~1419 Da | Neutral form |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Typical storage | -20 C | Dry powder, protected from moisture |
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
Mizell won his first start of 1953, coming within an out of throwing a complete game on April 22 against Cincinnati in an 8–3 victory. On April 28, he held the Phillies to one run for five innings in a tie, as rain forced the game to be called and it was never resumed. His most notable game of the season came on May 4, when he gave up just two hits in a shutout of the Pirates. Mizell had a 2.83 ERA before the All-Star Break, but he had a 4.14 ERA in the second half of the season. On August 7, he held the New York Giants to one run in a complete game, 2–1 triumph. Exactly one week later, he held Cincinnati to one run over nine innings, but the Cardinals only scored one for him. After throwing a scoreless 10th, Mizell took the loss in the 11th when Roy McMillan had an RBI single against him. His 11 strikeouts in that contest were a season-high, and he also had five games in which he had nine, including each of his last two starts. In 33 starts, he had a 13–11 record. For the second year in a row, he led the NL in strikeouts per 9 innings pitched (6.9), and he finished third in the league with 173 strikeouts this time, behind Roberts's 198 and Carl Erskine's 187. His 3.49 ERA was the ninth-best mark in the league, but his 114 walks trailed only Johnny Lindell's 139 for the league lead.
Public healthcare in Hong Kong is recognized for its high-quality medical outcomes. The territory has the highest life expectancy in the world at 85.9 years. Hong Kong has one of the lowest infant mortality rates in the world, with recent estimates placing it around 1.7 to 2.5 deaths per 1,000 live births. However, the public system also faces challenges, including high patient volumes, overcrowding in emergency departments, and long wait times for specialist appointments and elective procedures. Healthcare in Hong Kong is provided through two categories, consisting of public and private hospitals. While private hospital services cater to patients seeking shorter wait times and personalized care, the majority of the population relies on the extensive public healthcare system. Public hospitals and clinics are heavily subsidized by the government, ensuring affordable access to a wide range of medical services. Hong Kong's healthcare system is managed primarily by the Hospital Authority, which was established in 1990 to oversee and operate all public hospitals in the region. The system is organized into seven geographic clusters that group hospitals and associated healthcare facilities based on their distribution across the territory. As of 2026, Hong Kong has a total of 42 public hospitals and 11 private hospitals.
Beta-thalassemia (β-thalassemia) is an inherited blood disorder, a form of thalassemia resulting in variable outcomes ranging from clinically asymptomatic to severely anemic individuals. It is caused by reduced or absent synthesis of the beta chains of hemoglobin, the molecule that carries oxygen in the blood. Symptoms depend on the extent to which hemoglobin is deficient, and include anemia, pallor, tiredness, enlargement of the spleen, jaundice, and gallstones. In severe cases death ensues. Beta thalassemia occurs due to a mutation of the HBB gene leading to deficient production of the hemoglobin subunit beta-globin; the severity of the disease depends on the nature of the mutation, and whether or not the mutation is homozygous. The body's inability to construct beta-globin leads to reduced or zero production of adult hemoglobin thus causing anemia. The other component of hemoglobin, alpha-globin, accumulates in excess leading to ineffective production of red blood cells, increased hemolysis, and iron overload. Diagnosis is by checking the medical history of near relatives, microscopic examination of blood smear, ferritin test, hemoglobin electrophoresis, and DNA sequencing. As an inherited condition, beta thalassemia cannot be prevented although genetic counselling of potential parents prior to conception can propose the use of donor sperm or eggs. Patients may require repeated blood transfusions throughout life to maintain sufficient hemoglobin levels; this in turn may lead to severe problems associated with iron overload.
== Biosynthesis == Epothilone B is a 16-membered polyketide macrolactone with a methylthiazole group connected to the macrocycle by an olefinic bond. The polyketide backbone was synthesized by type I polyketide synthase (PKS) and the thiazole ring was derived from a cysteine incorporated by a nonribosomal peptide synthetase (NRPS). In this biosynthesis, both PKS and NRPS use carrier proteins, which have been post-translationally modified by phosphopantetheine groups, to join the growing chain. PKS uses coenzyme-A thioester to catalyze the reaction and modify the substrates by selectively reducing the β carbonyl to the hydroxyl (Ketoreductase, KR), the alkene (Dehydratase, DH), and the alkane (Enoyl Reductase, ER). PKS-I can also methylate the α carbon of the substrate. NRPS, on the other hand, uses amino acids activated on the enzyme as aminoacyl adenylates. Unlike PKS, epimerization, N-methylation, and heterocycle formation occurs in the NRPS enzyme.
Sources: en.wikipedia.org
Animals that commonly cause injury to plants include pests such as insects, mites, and nematodes. These variously bite or abrade plant parts such as leaves, stems, and roots, or as is common among the true bugs, pierce the plant's surface and suck plant juices. The resulting injuries may admit plant pathogens such as bacteria and fungi, which may extend the injury. Caterpillar larvae of agricultural pests such as cabbage white butterflies (Pieridae) can completely defoliate Brassica crops. Molluscs such as snails graze on plants including grasses and forbs, abrading them with their rasp-like radula; they can inflict substantial damage to crops. Grazing mammals including livestock such as cattle, too, bite off or break parts of plants including grasses, forbs, and forest trees, causing injury, and again, potentially admitting pathogens.
North Korea was one of the first countries to close borders due to COVID-19. Starting from 23 January 2020, North Korea banned foreign tourists, and all flights in and out of the country were halted. The authorities also started placing patients with suspected COVID, including those with slight, flu-like symptoms, in quarantine for two weeks in Sinuiju. On 30 January, the state news agency of North Korea, the Korean Central News Agency (KCNA), declared a "state emergency", and reported the establishment of anti-epidemic headquarters around the country. Though many parts of the border were closed, the bridge between Dandong and Sinuiju remained open and allowed supplies to be delivered. In late February, the North Korean government said that it would keep the border closed until a cure was found. On 2 February, KCNA reported that all the people who had entered the country after 13 January were placed under "medical supervision". South Korean media outlet Daily NK reported that five suspected COVID-19 patients in Sinuiju, on the Chinese border, had died on 7 February. The same day, The Korea Times reported that a North Korean female living in the capital Pyongyang was infected. Although there was no confirmation by North Korean authorities of the claims, the country implemented further strict measures to combat the spread of the virus. Schools were closed starting on 20 February. On 29 February, Supreme Leader Kim Jong Un called for stronger measures to be taken to prevent COVID-19 from spreading within North Korea.
== Patient-centric initiatives == In September 2016, Dr. Reddy's launched “Purple Health” in India, a patient centric platform to deliver solutions that address unmet needs of patients. Purple Health will address unmet needs of patients involving four segments: awareness, access (access to medication), adherence (adherence to therapy) and experience (simplified medication experience). The first step in this program will be the launch of new patient friendly packaging for its top 25 best-selling brands, which will be rolled-out in a phased manner over the next six months. The packaging has been designed such that blister packs would have extra space for brand name which ensures easy identification at the pharmacy, a tab at the bottom with expiry date clearly mentioned, and a pictorial representation of the time the medicine needs to be taken. In case of bottles, the measuring cup is now easy to read, and neck of the bottle has been modified to ensure minimal spillage. Purple Health also includes patient support services. For example, someone taking medicines for an advanced kidney condition would be supported by messages and counselling on diet, medicine and so on.
Sources: en.wikipedia.org
== External links == Nidogen at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: P10493 (Mouse Nidogen-1) at the PDBe-KB.
==== Type 3 ==== VWD type 3 is a rare but the most severe form of VWD. It occurs in individuals who are homozygous for the defective gene, resulting in a severe quantitative deficiency or complete absence of von Willebrand factor (VWF) production. In VWD type 3, VWF is undetectable in the VWF antigen assay. Since VWF normally protects coagulation factor VIII from proteolytic degradation, the total absence of VWF leads to extremely low factor VIII levels (typically 1-10%). These low levels are equivalent to those seen in severe hemophilia A, with clinical manifestations of life-threatening external and internal hemorrhages. The inheritance pattern of VWD type 3 is autosomal recessive, meaning that both parents must carry the defective gene for their child to be affected. In contrast, hemophilia A follows an X-linked recessive inheritance pattern. Additional diagnostic tools for VWD type 3 include assessing VWF activity using the Ristocetin cofactor assay and Collagen binding assay. In VWD type 3, VWF activity is either absent or approaching undetectable. VWF multimer analysis reveals no bands or very faint bands on electrophoresis. Additionally, Ristocetin-Induced Platelet Agglutination (RIPA) is typically absent or severely low.
== Traditional use == Peach gum has been documented in traditional Chinese medicine texts, including the Tang Bencao (Tang Materia Medica) and Li Shizhen's Bencao Gangmu (Compendium of Materia Medica) from the Ming Dynasty. Historical texts describe its use for treating urinary issues and other conditions, though these traditional uses have not been validated by modern scientific research.
== Gene == The COL2A1 gene is located on the long (q) arm of chromosome 12 between positions 13.11 and 13.2, from base pair 46,653,017 to base pair 46,684,527. The expression of COL2A1 is regulated by SOX-9 and retrotransposon gag-like-3 gene RTL3 in chondrocytes. There are two transcripts identified for this gene.
Sources: en.wikipedia.org
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.
No. The gastric protein is larger, while BPC-157 is a short fragment sequence. The peptide is produced synthetically for research use. The relationship is one of sequence origin, not chemical identity.
It is most often supplied as a lyophilized powder, frequently as the acetate salt. The powder is reconstituted with water or a buffer before use. Free-base and other salt forms also exist but are less common in catalogs.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.